International Journal of Hematology

Article	Citations
Differences in longitudinal growth patterns of children and adolescents with transfusion-dependent hemoglobin E/β-thalassemia and those achieving successful hematopoietic stem-cell transplantation	87
Comparison between filgrastim biosimilar and filgrastim original for the management of neutropenia after salvage chemotherapy for malignant lymphoma	52
Acute suppression of translation by hyperthermia enhances anti-myeloma activity of carfilzomib	50
Carcinocythemia diagnosed on peripheral blood clot sections	37
Treatment-related sequelae in Hodgkin’s lymphoma after mediastinal irradiation	30
Real-world treatment patterns and clinical outcomes in patients with AML in Japan who were ineligible for first-line intensive chemotherapy	25
NOVEL-1st: an observational study to assess the safety and efficacy of nilotinib in newly diagnosed patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase in Taiwan	25
Post-transfusion purpura and adult primary thrombocytopenia	24
Coexpression of natural killer cell antigens by T-cell large granular lymphocytes in hydroa vacciniforme lymphoproliferative disorder and the involvement of Vδ1 + epithelial-type γδT cells	24
Asciminib in patients with newly diagnosed chronic myeloid leukemia: results from the Japanese subgroup of ASC4FIRST	23
Tazemetostat for relapsed/refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan: 3-year follow-up for a phase II study	21
EVI1 upregulates PTGS1 (COX1) and decreases the action of tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia cells	21
Acute myeloid leukemia with NUP98::RARG rearrangement: a case report and review of the relevant literature	21
Changes in coagulation potential over time after administration of recombinant activated factor VII in an emicizumab-treated hemophilia A patient with inhibitors	21
IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice	20
Hexokinase II expression as a prognostic marker in diffuse large B-cell lymphoma: pre- and post-rituximab era	20
Ex vivo manufacturing of platelets: beyond the first-in-human clinical trial using autologous iPSC-platelets	19
WT1-guided pre-emptive therapy after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia	19
CEBPA mutations in acute myeloid leukemia: implications in risk stratification and treatment	19
Isolated thrombosis after COVID-19 vaccination: case series	18
Real-world toxicity and effectiveness of ixazomib, lenalidomide, and dexamethasone in Korean patients with relapsed and/or refractory multiple myeloma	18
Treatment trends and risks of corticosteroid use in adult primary immune thrombocytopenia: a claims database study in Japan	17
Reduced incidence of hemophagocytic lymphohistiocytosis in Japan during the COVID-19 pandemic	16
Efficacy and safety of recombinant porcine factor VIII in Japanese patients with acquired hemophilia A	15
Real-world data of AML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11)	15

Risk factors and remaining challenges in the treatment of acute promyelocytic leukemia	15
Possible prognostic impact of WT1 mRNA expression at day + 30 after haploidentical peripheral blood stem cell transplantation with posttransplant cyclophosphamide for patients with myeloid neoplasm: a	15
Humoral immunity after hematopoietic stem cell transplantation: evaluation by B-cell receptor repertoire analysis	15
Some key considerations regarding the design and evaluation of high-throughput sequencing-based biallelic chimerism assays	14
Armor sign on PET–CT in a young male with non-Hodgkin’s lymphoma	14
Progression to B acute lymphoblastic leukemia in 8p11 myeloproliferative syndrome with t(6;8)(q27;p12)	14
Effects of human herpesvirus 6B reactivation on cognitive function in cord blood transplant recipients: a prospective multicenter study	13
Real-world effectiveness of ixazomib, lenalidomide and dexamethasone in Asians with relapsed/refractory multiple myeloma	13
Sustained remission after cord blood transplantation for breast cancer with lung metastases and myelodysplastic syndrome	13
Chemotherapy-induced aseptic thrombophlebitis with an air bubble in the thrombus	13
Multicenter evaluation of the addition of eltrombopag to immunosuppressive therapy for adults with severe aplastic anemia	13
A case report of a truncated ABL1 mutation in 2 cases with Philadelphia chromosome-positive B cell precursor acute lymphoblastic leukemia	13
Primary pancreatic diffuse large B-cell lymphoma, appearing as an asymptomatic bulky mass with the duct-penetrating sign	13
Real-world bleeding outcomes and product utilization in people with severe-type hemophilia A before and after switching to extended half-life rFVIIIFc prophylaxis therapy	12
Current and emerging therapeutic strategies in adult T-cell leukemia–lymphoma	12
HLA haploidentical stem cell transplantation from HLA homozygous donors to HLA heterozygous donors may have lower survival rates than haploidentical transplantation from HLA heterozygous donors to HLA	12
Ten years’ experience in prenatal diagnosis of α-thalassemia in a municipal hospital and retrospective analysis of ultrasonic abnormalities	12
SPAG6 regulates cell proliferation and apoptosis via TGF-β/Smad signal pathway in adult B-cell acute lymphoblastic leukemia	12
Lymphoma during pregnancy in Japan: a multicenter retrospective cohort study	11
JSH practical guidelines for hematological malignancies, 2023: II. lymphoma—overview	11
Comparative inhibitory effects of bepotastine and diphenhydramine on rituximab-induced infusion reactions	11
Nodal mature plasmacytoid dendritic cell proliferation mimicking lymphoma in a patient with CALR-mutated myelofibrosis	11
Efficacy of polatuzumab vedotin versus conventional chemotherapy in relapsed or refractory diffuse large B-cell lymphoma	11
Three atypical BCR/ABL transcripts detected simultaneously in a Philadelphia-positive acute lymphoblastic leukemia patient showing resistance to tyrosine kinase inhibitors	11
Maintenance therapy after allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma	11
Evolution and optimization of therapies for acute lymphoblastic leukemia in infants	11
Validation of an algorithm for identifying patients with febrile neutropenia: an epidemiological study using real-world data in Japan	11
Retrospectively diagnosed autoimmune VWF deficiency in a patient with repeated hemorrhagic events after two common colds	11
Bone marrow ring sideroblasts in hematological diseases: an analysis of consecutive 1300 samples in a single institution	10
Guest Editorial: what can be done to improve cancer immunotherapies?	10
Clinical and genetic features of Japanese cases of MDS associated with VEXAS syndrome	10
Dose optimization of tyrosine kinase inhibitor therapy in chronic myeloid leukemia	10
Assay variables and early clinical evaluation of low-angle light scattering for platelet function analysis	10
Correction to: A phase I study of inotuzumab ozogamicin as a single agent in pediatric patients in Japan with relapsed/refractory CD22-positive acute lymphoblastic leukemia (INO-Ped-ALL-1)	10
Romidepsin-induced durable remission for relapsed nodal peripheral T-cell lymphoma with T follicular helper phenotype after allogeneic hematopoietic cell transplantation	9
DLI-induced remission in recurrent EBV-associated T/NK-cell lymphoproliferative disease following HSCT: a case report	9
Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study	9
Retrospective analysis of treatment discontinuation in minimal residual disease negative multiple myeloma	9
Influence of FOXP3 single-nucleotide polymorphism after allogeneic hematopoietic stem cell transplantation	9
Correlation of ex vivo and in vivo ammonia production with L-asparaginase biological activity in adults with lymphoid malignancies	9
Phase 2 study of combination chemotherapy with bortezomib in children with relapsed and refractory acute lymphoblastic leukemia	9
Multiple myeloma with high-risk cytogenetics and its treatment approach	9
Management of inpatient chimeric antigen receptor T-cell therapy for relapsed/refractory B-cell malignancies: an analysis using the Japanese Diagnosis Procedure Combination database	9
Combined tumor necrosis factor-α (−308 G/A) and tumor necrosis factor-β (+ 252 A/G) nucleotide polymorphisms and chronicity in Egyptian children with immune thrombocytopenia	9
Letter to the Editor: Very low-dose antithymocyte globulin (thymoglobulin) is effective for steroid-refractory acute graft-versus-host disease involving the skin or gut after allogeneic hematopoietic	9
Effect of delivery mode on postnatal platelet count dynamics in neonates born to mothers with immune thrombocytopenia	9
Sequential occurrence of BCR::ABL1-negative MPN and CML and vice versa: results from a real world cohort	9
Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) in Japan 2023	9
Association between the pharmacokinetics of rabbit anti-thymocyte globulin and acute graft-versus-host disease in patients who received haploidentical hematopoietic stem cell transplantation	8
Improvement of immune thrombocytopenia with imatinib therapy following chronic myeloid leukemia	8

Therapy-related acute myeloid leukemia with inv(16)(p13.1q22)	8
Clinical features of immature leukemias in children	8
Asciminib in Patients With CML-CP Previously Treated With ≥ 2 Tyrosine Kinase Inhibitors: 96-Week Results From the Japanese Subgroup Analysis of the ASCEMBL Study	8
An adult case of refractory autoimmune neutropenia after liver transplantation	8
Skin complications during iron chelation therapy for beta-thalassemia: overview and treatment approach	8
COVID-19 omicron variant outbreak in a hematopoietic stem cell transplant unit	8
Tumor lysis syndrome in induction therapy for acute myeloid leukemia before the rasburicase era	8
Transplantation outcomes of TP53-mutant AML and MDS: a single transplantation center experience of 63 patients	8
Resilient T-cell responses in patients with advanced cancers	8
Detection of Talaromyces marneffei in a HIV-infected patient from peripheral blood observation through Sysmex XN WNF/WNR channels	8
Auer rods in mature granulocytes in peripheral blood	8
A phase I study of inotuzumab ozogamicin as a single agent in pediatric patients in Japan with relapsed/refractory CD22-positive acute lymphoblastic leukemia (INO-Ped-ALL-1)	8
Age-related variation in coagulation factors in non-valvular atrial fibrillation patients receiving direct oral anticoagulants	8
Prognostic significance of age at diagnosis and preceding infection varies across age groups in childhood immune thrombocytopenia	7
Prognostic impacts of serum levels of C-reactive protein, albumin, and total cholesterol in patients with myelodysplastic syndromes	7
Clinical significance of total nucleated cell count in bone marrow of patients with acute lymphoblastic leukemia who underwent allogeneic hematopoietic stem cell transplantation	7
Prophylactic or preemptive tyrosine kinase inhibitor therapy after allogeneic hematopoietic cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia	7
Correction: Efficacy and safety of equine anti-thymocyte immunoglobulin (eATG) in three Japanese patients with moderate to very severe aplastic anemia: a case series	7
Venetoclax and azacitidine in combination with homoharringtonine, cytarabine, and aclarubicin for salvage therapy of relapsed/refractory T cell acute lymphoblastic leukemia	7
A retrospective survey of patients who discontinued participation in the JPLSG HLH-2004 clinical trial	7
Sarcopenia and clinical outcomes in lymphoma and multiple myeloma patients receiving hematopoietic cell transplantation: a systematic review and meta-analysis	7
A phase 2 trial of VRD induction for transplant-eligible Japanese patients with newly diagnosed multiple myeloma	7
Myeloid leukemoid reaction after initial azacitidine therapy for chronic myelomonocytic leukemia	7
Dysregulated hemostasis in acute promyelocytic leukemia	7
Leukemic-phase mucosa-associated lymphoid tissue lymphoma	7
Longitudinal dynamic changes in factor VIII inhibitor titers in patients with hemophilia A and inhibitors receiving emicizumab prophylaxis	7
COVID-19 microthrombosis: unusually large VWF multimers are a platform for activation of the alternative complement pathway under cytokine storm	7
Clinicopathological characteristics associated with the engraftment of patient lymphoma cells in NOG mice	7
Introduction of the T315I gatekeeper mutation of BCR/ABL1 into a Philadelphia chromosome-positive lymphoid leukemia cell line using the CRISPR/Cas9 system	7
Prevention of venous thromboembolism in pregnant women with congenital antithrombin deficiency: a retrospective study of a candidate protocol	7
Japanese and French translation and linguistic validation of a patient-reported outcome tool to assess quality of life in patients with Immune Thrombocytopenia (ITP): the ITP Life Quality Index (ILQI)	7
Clinical practice guidelines for management of disseminated intravascular coagulation in Japan 2024. Part 1: sepsis	7
Langerhans cell histiocytosis with mesenteric involvement successfully treated with trametinib: a rare cause of small intestine obstruction	7
Pseudo-Chediak–Higashi inclusions and Auer rods in a case of therapy-related acute monocytic leukemia	7
Long-term efficacy and safety profile of splenectomy for pediatric chronic immune thrombocytopenia	7
A novel stroma-dependent leukemia cell line from a patient with mixed-phenotype acute leukemia with Ph chromosome and PAX5 mutation	7
Recent advances in the diagnosis and treatment of pediatric acquired aplastic anemia	7
TBI, etoposide, and cyclophosphamide conditioning for intermediate-risk relapsed childhood acute lymphoblastic leukemia	6
A rare case of concurrent metastatic breast cancer and follicular lymphoma diagnosed by lymph node biopsy: a case report	6
Integrin β5 and β7 expression in lenalidomide-resistant multiple myeloma cells	6
FLT3 targeting in the modern era: from clonal selection to combination therapies	6
JSH practical guidelines for hematological malignancies, 2023: leukemia-2—acute promyelocytic leukemia (APL)	6
Expansion effect of romiplostim on hematopoietic stem and progenitor cells versus thrombopoietin and eltrombopag	6
Correction to: Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal?	6
Hematopoietic cell transplantation in pediatric EB virus-associated hemophagocytic lymphohistiocytosis	6
Clinical characteristics of late-onset interstitial pneumonia after allogeneic hematopoietic stem cell transplantation	6
Cardiovascular toxicity from tyrosine kinase inhibitors in chronic myeloid leukemia with severe dilated cardiomyopathy	6
The mutual crosstalk between iron and erythropoiesis	6
Management of lymphoma-associated chylothorax by interventional radiology and chemotherapy: a report of five cases	6
Real-world safety profile of eculizumab in patients with paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, or generalized myasthenia gravis: an integrated analysis of post-marke	6
Severe short-term adverse events in related bone marrow or peripheral blood stem cell donors	6
A case of posttransplant isolated extramedullary relapse of acute lymphoblastic leukemia achieving durable treatment-free remission with blinatumomab and donor lymphocyte infusion	6
Characterization of congenital factor XII deficiency in Taiwanese patients: identification of one novel and one common mutation	6
Ex vivo expansion and activation of Vγ9Vδ2 T cells by CELMoDs in combination with zoledronic acid	6
Severe infections and renal dysfunction during immunosuppressive therapy with cyclosporine A for aplastic anemia	6
Venetoclax with CAG regimen for early T-cell precursor acute lymphoblastic leukemia: a case report and literature review	6
Modeling and therapeutic targeting of t(8;21) AML with/without TP53 deficiency	6
Frontiers in pathophysiology and management of thrombotic thrombocytopenic purpura	6
Recent advances in understanding the biology of follicular lymphoma	6
Neuropeptide TIP39 induces autophagy in PTH2 receptor-positive myeloid neoplasms	6
An expanded-access clinical study of thiotepa (DSP-1958) high-dose chemotherapy before autologous hematopoietic stem cell transplantation in patients with malignant lymphoma	5
FNAIT pathogenesis determined by serial analysis of three subsequent pregnancies of a woman with severe fetal and neonatal alloimmune thrombocytopenia (FNAIT) with anti-HPA-4b and anti-HPA-5b alloanti	5
Pneumatic tube transport-induced pseudohyperkalemia in patients with extreme leukocytosis: a retrospective study from a single medical center	5
Bilateral development of biclonal ocular adnexal marginal zone lymphoma at a 2-year interval	5
Clinical diagnostic accuracy of respiratory failure in critically ill hematopoietic stem cell transplant patients	5
NK-cell post-transplant lymphoproliferative disease successfully treated by second allogenic hematopoietic stem cell transplantation in chronic active Epstein–Barr virus infection	5
Stem cell regulation and dynamics in myeloid malignancies	5
A phase 1/2 study of gilteritinib in combination with chemotherapy in newly diagnosed patients with AML in Asia	5
Decreased incidence of acute immune thrombocytopenia in children during the COVID-19 pandemic	5
A phase 2 clinical trial of luspatercept in non-transfusion-dependent patients with myelodysplastic syndromes	5
VEXAS syndrome	5
Prognostic model for relapsed/refractory transplant-ineligible diffuse large B-cell lymphoma utilizing the lymphocyte-to-monocyte ratio	5
HLA-haploidentical T-cell receptor αβT/B-cell-depleted stem cell transplantation for Fanconi anemia	5
Correction: JSH practical guidelines for hematological malignancies, 2023: leukemia-2—acute promyelocytic leukemia (APL)	5
Recent advances in AML with mutated NPM1	5
Radiation-sparing reduced-intensity unrelated umbilical cord blood transplantation for rare hematological disorders in children	5
Mature T-cell and NK-cell lymphomas: updates on molecular genetic features	5
New onset of hypomegakaryocytic thrombocytopenia with the potential for progression to aplastic anemia after BNT162b2 mRNA COVID-19 vaccination	5
Japanese phase Ib study of the oral PI3K-δ and -γ inhibitor duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma	5
Massive pleural effusion as the initial presentation of Waldenström macroglobulinemia: rare extramedullary involvement	5

Heme as a differentiation-regulatory transcriptional cofactor	5
Novel immunotherapies in multiple myeloma	5
JSH practical guidelines for hematological malignancies, 2023: II. Lymphoma 4. Mantle cell lymphoma (MCL)	5
A Phase 1/2 study of teclistamab, a humanized BCMA × CD3 bispecific Ab in Japanese patients with relapsed/refractory MM	5
Guest editorial: recent progress in pediatric leukemia	5
Reduced OTUD7B expression correlates with poor prognosis in PTCL via non-canonical NF-κB	5
Spontaneous regression of multiple solitary plasmacytoma harboring Epstein–Barr virus: a case report and literature review	5
MYC-rearranged blastic plasmacytoid dendritic cell neoplasm with immunoblastoid features	5
Thiotepa-based high-dose chemotherapy with autologous stem cell transplantation for neurolymphomatosis	5
Septic shock caused by Capnocytophaga canimorsus in a patient with heterozygous Pelger-Huët anomaly	5
Erythroblast predominance without CD41/cyCD41-positive blasts predicts favorable prognosis in patients with myelodysplastic syndromes and acute myeloid leukemias treated with azacitidine	5
Burkitt in disguise: clonal transformation of incidentally detected gallbladder diffuse large B-cell lymphoma in a liver transplant recipient	5
Identification and functional analysis of three novel genetic variants resulting in premature termination codons in three unrelated patients with hereditary antithrombin deficiency	5
Reply to the Dr. Murphy’s comment	5
Association between early corticosteroid administration and long-term survival in non-infectious pulmonary complications after allogeneic hematopoietic stem cell transplantation	4
Post-remission measurable residual disease directs treatment choice and improves outcomes for patients with intermediate-risk acute myeloid leukemia in CR1	4
A successful control of cardiac amyloidosis by idecabtagene vicleucel in a patient with relapsed and refractory multiple myeloma: a case report and literature review	4
Favorable outcomes of allogeneic hematopoietic stem cell transplantation with fludarabine–bendamustine conditioning and posttransplantation cyclophosphamide in classical Hodgkin lymphoma	4
Comparison of disease and risk classifications of AML before and after incorporation of NGS analysis of bone marrow samples	4
Multifocal osteonecrosis after stem cell transplantation	4
Therapeutic impact of mesenchymal stem cells on idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation	4
Ropeginterferon-α2b discontinuation after long-term exposure: four cases from a single institution	4
In vitro evaluation of global coagulation potential of emicizumab and warfarin using rotational thromboelastometry	4
A phase 1/2 study of NS-87/CPX-351 (cytarabine and daunorubicin liposome) in Japanese patients with high-risk acute myeloid leukemia	4
Factor XII deficiency: a clinical and molecular genetic study	4
Characteristics and literature review of ETV6::ABL1 fusion gene-positive acute myeloid leukemia	4
Front-line fludarabine-cyclophosphamide-rituximab (FCR) in 110 patients with chronic lymphocytic leukaemia (CLL): real-life experience with long-term outcomes, toxicities and responses to second-line	4
Long-term immunity to measles and rubella after vaccination in adult allogeneic hematopoietic stem cell transplant recipients	4
Development of TCR-T cell therapy targeting mismatched HLA-DPB1 for relapsed leukemia after allogeneic transplantation	4
Effects of second transplantation with T-cell-replete haploidentical graft using low-dose anti-thymocyte globulin on long-term overall survival in pediatric patients with relapse of leukemia after fir	4
Safety and antitumor activity of copanlisib in Japanese patients with relapsed/refractory indolent non-Hodgkin lymphoma: a phase Ib/II study	4
Histological confirmation and radiotherapy facilitate continuation of epcoritamab in a patient with tumor flare reaction	4
Bringing mass spectrometry into the care of patients with multiple myeloma	4
Knockdown of the Shwachman-Diamond syndrome gene, SBDS, induces galectin-1 expression and impairs cell growth	4
Anakinra for the treatment of adult secondary HLH: a retrospective experience	4
A retrospective analysis of clinicopathological and genetic features of synchronous CNS and systemic DLBCL at diagnosis	4
Post-marketing surveillance of the safety and effectiveness of nivolumab for classic Hodgkin lymphoma in Japan	4
A case of late-onset sinusoidal obstruction syndrome diagnosed histologically before meeting diagnostic criteria	4
Bosutinib-induced lung injury: a report of two cases and literature review	4
Impact of center volume on acute graft versus host disease in allogeneic stem cell transplant recipients	4
Blasts engulfing erythrocytes: an unusual morphological finding in adult early T-precursor acute lymphoblastic leukemia	4
Long-range and real-time PCR identification of a large SERPINC1 deletion in a patient with antithrombin deficiency	4
Efficacy of alternate day versus daily oral iron therapy in children with iron deficiency anemia: a randomized controlled trial.	4
Disappearance of bulky diffuse large B-cell lymphoma after methotrexate/infliximab withdrawal	4
Outcomes of salvage haploidentical transplantation using posttransplant cyclophosphamide for graft failure following allogeneic hematopoietic stem cell transplantation	4
Impact of muscle loss in children with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation	4
Vedolizumab for children with intestinal graft-versus-host disease: a case report and literature review	4
Tertiary prophylaxis with extended half-life factor prophylaxis: a model to reduce disability in low- and middle-income countries	4
JSH Practical Guidelines for Hematological Malignancies, 2023: II. Lymphoma—2. Marginal zone lymphoma: MZL (extranodal marginal zone lymphoma: EMZL [extranodal marginal zone lymphoma of mucosa associa	4
Plasma proteomics associated with autoimmune coagulation factor deficiencies reveals the link between inflammation and autoantibody development	4
Correction: Real‑world safety profile of eculizumab in patients with paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, or generalized myasthenia gravis: an integrated analysis o	4
Retrospective nationwide survey of pediatric RDD in Japan: a high prevalence of mutations in the kinase pathway genes	4
JSH practical guidelines for hematological malignancies, 2023: II. Lymphoma5. Diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS)	4
Pulmonary hypertension is associated with poor cardiovascular and hematologic outcomes in patients with myeloproliferative neoplasms and cardiovascular disease	4
JSH practical guidelines for hematological malignancies, 2023 III. Myeloma 2. Related disorders of multiple myeloma	4
Successful autologous stem cell transplantation in a case of central nervous system relapse of diffuse large B-cell lymphoma with concurrent polycythemia vera	4
Epigenetics in lymphocyte and lymphoma: EZH2 as an easy-to-access therapeutic target?	4
Correction: JSH practical guidelines for hematological malignancies, 2023: I. Leukemia-1. Acute myeloid leukemia (AML)	4
Correction to: A phase II study of post‑transplant cyclophosphamide combined with tacrolimus for GVHD prophylaxis after HLA‑matched related/unrelated allogeneic hematopoietic stem cell transplantation	4